此外，浦银国际指出，公司股票于4月2日起停牌，停牌期间审计师除对披露的金融资产进行审计外，也延伸核查了公司多项财务及内控项目，且最终出具标准无保留意见，一定程度上为沛嘉提供了更强有力的审计背书，或可提高投资人对公司财务及内控的信心。Peijia Medical -B (09996) rose more than 14% in the last trading session, with a cumulative increase of more than 30% in the past six trading days. As of press time, it rose 11.36% to HKD 2.94, with a turnover of HKD 16.3782 million.
Peijia Medical -B (09996) rose more than 14% in the last trading session, with a cumulative increase of more than 30% in the past six trading days. As of press time, it rose 11.36% to HKD 2.94, with a turnover of HKD 16.3782 million.
On the news front, Peijia Medical recently announced a share buyback plan. The board of directors will decide whether to buy back company shares on the open market based on market conditions. According to the share repurchase authorization, the company is allowed to repurchase up to a maximum of 10% of the total number of shares issued as of the date of the 2022 shareholder annual meeting, up to a maximum of 67.8857 million shares.
In addition, Pujiang International pointed out that the company's stock was suspended from trading on April 2. During the suspension period, the auditor not only audited the disclosed financial assets, but also extended the audit to multiple financial and internal control items of the company. Eventually, the auditor issued a standard unqualified opinion, which to some extent provided a strong audit endorsement for Peijia, and may improve investors' confidence in the company's financial and internal control.
